



## (51) International Patent Classification:

*A61K 38/17* (2006.01) *C07K 19/00* (2006.01)*A61P 9/10* (2006.01)

## (21) International Application Number:

PCT/IB2021/051405

## (22) International Filing Date:

19 February 2021 (19.02.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/978,759 19 February 2020 (19.02.2020) US

62/978,792 19 February 2020 (19.02.2020) US

(71) Applicant: **NONO INC.** [CA/CA]; 479A Wellington St. W, Toronto, Ontario M5V 1E7 (CA).(72) Inventors: **TYMIANSKI, Michael**; 175 Dawlish Avenue, Toronto, Ontario M4N 1H6 (CA). **GARMAN, Jonathan David**; 148 Lawrie Road, Thornhill, Ontario L4J 8N1 (CA).

## (81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION TREATMENT OF STROKE WITH PLASMIN-CLEAVABLE PSD-95 INHIBITOR AND REPERFUSION




FIG. 10B

(57) Abstract: The peptide inhibitor of PSD-95, Tat-NR2B9c, is cleaved by the serum protease, plasmin, inducible by thrombolytic agents. Conversely, Tat-NR2B9c has no detrimental effect on the activity of a thrombolytic agent. Inactivation of Tat-NR2B9c by thrombolytic agents can be reduced or avoided by several approaches including spacing the administration of the respective agents to avoid substantial overlap in plasma residence between Tat-NR2B9c and plasmin, using mechanical instead of thrombolytic reperfusion or using active agent that inhibits PSD-95 not subject to cleavage by plasmin, e.g., D-amino acid variants of Tat-NR2B9c.

[Continued on next page]



**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*